无锡智康弘仁

Zhikang Biopharma is a clinical-stage biotechnology company based in Wuxi, China, dedicated to developing next-generation therapies for metabolic disorders. The company specializes in the discovery and development of long-acting peptide drugs, with a primary focus on multi-target agonists for the treatment of obesity and type 2 diabetes. Its lead candidate, ZK002, is a dual GLP-1/GIP receptor agonist currently in clinical development. By utilizing its proprietary peptide optimization platform, Zhikang Biopharma aims to address the significant unmet medical needs in the global metabolic disease market. The company is backed by prominent venture capital firms including Qiming Venture Partners and Matrix Partners China.